The American Lung Association’s “State of Lung Cancer” report reveals new national and state lung cancer data and calls on Congress to pass the Clinical Trial Modernization Act.



RT’s Three Key Takeaways:

  1. Rising Survival Rates: The US five-year lung cancer survival rate has reached 31.0%, up from 18.1% nine years ago.
  2. Screening Gaps: Only 24.4% of eligible high-risk individuals in the US receive annual low-dose computed tomography (CT) screenings, with rates varying widely by state.
  3. Care Disparities: Nationally, 20.9% of patients receive no treatment following diagnosis, and significant survival gaps persist among racial and ethnic groups.


The five-year lung cancer survival rate in the US has increased from 18.1% to 31.0% over the past nine years, according to the ninth annual “State of Lung Cancer” report released by the American Lung Association (ALA). Despite these improvements, lung cancer remains the leading cause of cancer deaths in the nation, with an estimated 229,410 individuals expected to receive a diagnosis this year.

According to the report, advances in lung cancer research have led to dozens of new treatment options this year alone, while increased access to lung cancer screening helps detect the disease earlier, and expanded use of biomarker testing helps guide treatment decisions.

“Lung cancer is a devastating disease, but the positive trends detailed in our latest report offer hope. Since our first report only nine years ago, the national five-year survival rate has increased significantly, from 18.1% to 31.0%, and screening rates have also continued to rise. Unfortunately, not all communities have benefitted from this progress,” said Harold Wimmer, President and CEO of the American Lung Association. “Awareness is still low and challenges remain. We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis.”

Clinical trials are essential to improving outcomes for people affected by lung cancer and advancing research. Trials are used to evaluate new approaches to early detection and treatment that may be more effective. However, too many people face barriers that prevent them from participating in clinical trials.

The American Lung Association is urging Congress to pass the Clinical Trial Modernization Act, which includes critical steps to make clinical trials accessible to more people and advance research and care for all.

The “State of Lung Cancer” report details national and state trends in the following key indicators:

  • New Cases: More than 229,000 people will be diagnosed with lung cancer this year, with the rate of new cases varying by state. The national rate of five-year lung cancer incidence was 52.1 (per 100,000 people). The rate of new cases was best in Utah (24.6) and worst in Kentucky (83.9).
  • Survival: Lung cancer has one of the lowest five-year survival rates because cases are often diagnosed at later stages, when the cancer has spread and treatment options are less likely to be curative. The national average of people alive five years after a lung cancer diagnosis is 31.0%. Survival rates were best in Massachusetts (40.9%) and worst in Alabama (23.8%).
  • Early Diagnosis: The earlier lung cancer is diagnosed, the more likely treatments will be effective. Nationally, only 29.3% of cases are diagnosed at an early stage. Early diagnosis rates were best in Rhode Island (38.0%) and worst in Hawaii (21.9%).
  • Surgical Treatment: Lungcancer can often be treated with surgery if it is diagnosed at an early stage and has not spread. Nationally, 21.4% of cases underwent surgery. Surgical treatment rates were best in Massachusetts (32.7%) and worst in New Mexico (12.7%).
  • Lack of Treatment: Nationally, 20.9% cases received no treatment. While there are multiple reasons why people may not receive treatment after a lung cancer diagnosis, no one should go untreated because of lack of provider or patient knowledge, lung cancer stigma, fatalism after diagnosis or cost of treatment. Lack of treatment rates were best in Rhode Island (13.4%) and worst in Nevada (36.7%).
  • Lung Cancer Screening: Lung cancer screening with an annual low-dose CT scan is the best way to detect lung cancer at an early stage, when it is more likely to be curable. But too few people at high risk for lung cancer are getting screened. The report finds that nationally, only 24.4% of people eligible for this lifesaving test have been screened, and screening rates vary widely by state. Lung cancer screening rates were best in Massachusetts (38.7%) and worst in South Dakota (13.5%).
  • Comprehensive Coverage of Biomarker Testing: Biomarker testing can help identify more effective treatments for a person’s specific type of lung cancer, including targeted therapies and immunotherapy. Insurance coverage is important for making biomarker testing more affordable for people. 19 states require coverage for comprehensive biomarker testing and 7 states require some coverage. However, 24 states and Washington, D.C., do not require coverage of biomarker testing.

The report also reveals differences in lung cancer outcomes among communities. Survival rates were highest for Asian and Pacific Islander individuals, Latino individuals and white individuals, who have survival rates of 35.4%, 30.8% and 30.8%, respectively; however, survival rates are significantly lower among Black individuals at 26.1% and Indigenous individuals at 18.2%, compared to white individuals. Overall, the report finds that people of color who are diagnosed with lung cancer are less likely to be diagnosed early, less likely to receive surgical treatment and more likely to receive no treatment.

There are a variety of risk factors associated with lung cancer, including smoking and exposure to radon gas, air pollution and secondhand smoke. Radon testing and mitigation, measures to limit air pollution, and reducing smoking rates through well-funded tobacco prevention and control programs, tobacco tax increases, smokefree air laws and access to comprehensive quit smoking services are all ways to help reduce the risk of lung cancer cases.

The American Lung Association brings research, advocacy and health promotions together to address lung cancer; investing in science, advocating for better access to prevention and care; and providing education, support and resources to help individuals navigate timely access to screening, diagnosis and treatment.